198 related articles for article (PubMed ID: 16891466)
1. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
[TBL] [Abstract][Full Text] [Related]
2. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
3. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
4. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the level of RRM1 expression and the sensitivity to gemcitabine in the esophageal squamous cell carcinoma cell lines].
Luo Y; Lin C; Zhang XY; Liang X; Fu M; Feng FY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):660-3. PubMed ID: 20021860
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
Le Chevalier T
Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
[TBL] [Abstract][Full Text] [Related]
10. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Marini L; Del Tacca M; Danesi R
Mol Pharmacol; 2005 Jul; 68(1):110-8. PubMed ID: 15795320
[TBL] [Abstract][Full Text] [Related]
11. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer.
Bessho Y; Oguri T; Ozasa H; Uemura T; Sakamoto H; Miyazaki M; Maeno K; Sato S; Ueda R
Oncol Rep; 2009 Jan; 21(1):263-8. PubMed ID: 19082471
[TBL] [Abstract][Full Text] [Related]
12. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Tsai MS; Kuo YH; Chiu YF; Su YC; Lin YW
J Pharmacol Exp Ther; 2010 Dec; 335(3):830-40. PubMed ID: 20855443
[TBL] [Abstract][Full Text] [Related]
14. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
18. The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
Ngeow J; Toh CK
Curr Drug Targets; 2010 Jan; 11(1):61-6. PubMed ID: 19839926
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics and gemcitabine.
Rosell R; Cobo M; Isla D; Camps C; Massuti B
Ann Oncol; 2006 May; 17 Suppl 5():v13-16. PubMed ID: 16807441
[TBL] [Abstract][Full Text] [Related]
20. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.
Oguri T; Ozasa H; Uemura T; Bessho Y; Miyazaki M; Maeno K; Maeda H; Sato S; Ueda R
Mol Cancer Ther; 2008 May; 7(5):1150-5. PubMed ID: 18445659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
